



## Radiofrequency Ablation of Atrioventricular Nodal Reentry Tachycardia: A 14 Year Experience with 901 Patients at the Tel Aviv Sourasky Medical Center

Ian Topilski MD\*, Ori Rogowski MD\*, Aharon Glick MD, Sami Viskin MD, Michael Eldar MD and Bernard Belhassen MD

Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel  
Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel

**Key words:** atrioventricular nodal reentry tachycardia, radiofrequency ablation

### Abstract

**Background:** Atrioventricular nodal reentry tachycardia is the most frequent cause of regular, paroxysmal supraventricular tachycardia. Radiofrequency ablation of the slow pathway has been recommended as first-line therapy for curing AVNRT.

**Objectives:** To report a 14 year experience of RFA of the slow pathway in patients with AVNRT treated in our laboratory.

**Methods:** A total of 901 consecutive patients (aged 9–92, mean  $50.8 \pm 18.2$  years) underwent RFA of the slow pathway. All patients had sustained AVNRT induced with or without intravenous administration of isoproterenol. A standard electrophysiologic method with three diagnostic and one ablation catheter was used in 317 patients (35.2%); in the remaining 584 patients (64.8%), only two electrode catheters (one diagnostic, one ablation) were used ("two-catheter approach").

**Results:** Catheter ablation of the slow pathway abolished AVNRT induction in 877 patients (97.3%). In 14 patients (1.6%) the procedure was discontinued while in 10 (1.1%) the procedure failed. In 864 patients (95.9%) there were no complications. Transient or permanent AV block occurred during the procedure in 31 patients (3.4%), of whom 8 (0.9%) eventually required pacemaker insertion ( $n=7$ ) or upgrade of a previously implanted VVI pacemaker ( $n=1$ ) during the month following the procedure. The number of catheters used did not significantly affect the rate of results or complications of the ablation procedure. The success and complication rates remained stable over the years, although a significant trend for increased age and associated heart disease was observed during the study period.

**Conclusions:** The results of this single-center large study, which included patients with a wide age range, showed results similar to those of previous studies. The use of a "two-catheter approach" (one diagnostic and one ablation) was as effective and safe as a multi-catheter approach.

*IMAJ 2006;8:455–459*

For Editorial see page 497

\* Dr. Topilski and Dr. Rogowski contributed equally to the study

AVNRT = atrioventricular nodal reentry tachycardia

RFA = radiofrequency ablation

Atrioventricular nodal reentry tachycardia is the most frequent cause of regular, paroxysmal supraventricular tachycardia. The mechanism of AVNRT is classically attributed to dual AV nodal pathways physiology, including one with relatively fast conduction but long antegrade refractoriness (fast pathway) and another with slower conduction but shorter antegrade refractoriness (slow pathway) [1]. However, this concept likely results from functional properties of anisotropic tissue within the triangle of Koch rather than anatomically distinct pathways [1]. The slow pathway is located along the postero-medial tricuspid annulus close to the coronary sinus ostium. Since its introduction in the early 1990s [2–6], RFA of the slow pathway has become first-line therapy for AVNRT. Slow pathway ablation is guided by a combination of fluoroscopic landmarks, electrogram morphology, and the induction of junctional rhythm during the application of RF energy. Although the success rate of slow pathway ablation is as high as 97%, it may be complicated by severe AV nodal conduction disturbances that require permanent pacemaker implantation in 0.9–2% of patients [2–15].

We report here the clinical features, electrophysiologic characteristics, results of RFA, and long-term outcome in all patients who underwent RFA of AVNRT in our laboratory. The evolution of procedural methods and the complications observed during the study period are emphasized.

### Patients and Methods

#### Patients

The study group comprised 901 consecutive patients who underwent RFA of AVNRT during a 14 year period (January 1992 to December 2005). The patients were divided into four equal groups according to the time of the RFA procedure. During the baseline electrophysiologic study, all patients had sustained AVNRT induced before or after intravenous administration of isoproterenol. One of the investigators (B.B.) participated in all but six of the ablation procedures.

### **Electrophysiologic study**

After the patients gave informed consent, the electrophysiologic study was performed using standard techniques [16]. In the early years a multi-catheter approach was used, including the placement of three diagnostic electrode catheters in the coronary sinus, the right ventricular apex and the His bundle area, as well as an ablation catheter. Later, a "two-catheter approach" using a single diagnostic electrode catheter (placed in the high right atrium) and an ablation catheter was employed. A multi-catheter approach was also used for ablation of AVNRT when the mechanism of PSVT was unclear or after ablation of another arrhythmia. The ablation catheter was usually a Mansfield/Cordis/Webster catheter (temperature-guided or not) and less commonly a temperature-guided catheter (EP Technologies, Boston Scientific, MA, USA).

The baseline electrophysiologic study included atrial stimulation (rapid atrial pacing and/or delivery of one to three extrastimuli) as well as ventricular stimulation if AVNRT was not induced with atrial stimulation. If sustained AVNRT (lasting  $\geq 30$  sec) was not induced with this protocol, isoproterenol (1  $\mu\text{g}/\text{min}$ ) was administered at incremental dosage until the basic sinus rhythm increased by  $\geq 20\%$ , and the stimulation protocol was repeated.

### **Definitions**

Dual AV node physiology was defined as a  $\geq 50$  msec increment in atrium-to-His (AH) or PR interval following a 10 msec decrement in coupling interval during single atrial extrastimulation or a  $\geq 50$  msec increment in AH or PR interval in consecutive beats after a 10 msec decrement in pacing cycle length during incremental atrial pacing [15].

### **Ablation procedure**

RFA of the slow AV nodal pathway was performed according to a standard combined electrophysiologic-anatomic approach [17]. Briefly, the catheter tip of the ablation catheter was positioned at the His bundle area and progressively withdrawn along the tricuspid annulus, starting at the most posterior site (near the coronary sinus ostium) and progressing to the more anterior locus (closer to the His bundle recording site). RF energy was delivered with a temperature setting of 55–60°C using an initial 26 Watts power that was gradually increased up to 60 Watts if necessary. If an accelerated junctional rhythm was recognized within 30 seconds, the energy delivery was continued for a total of 1 minute. Administration of RF energy was discontinued upon occurrence of AV block, very rapid junctional rhythm, retrograde block during junctional rhythm, impedance rise, catheter displacement or severe chest pains.

Ablation of the slow pathway was diagnosed when, after RF application, dual AV node physiology could no longer be demonstrated and neither AV nodal echoes nor AVNRT could be induced with and without isoproterenol infusion.

Modification of the slow pathway was defined as the persis-

tence of dual AV node physiology and inducible 1-3 AV nodal echo beats but no inducible AVNRT with and without isoproterenol infusion.

Catheter-induced mechanical trauma to slow and/or fast pathway was observed in 121(13.4%) of the study patients. A separate report dealing with this observation will be published elsewhere.

### **Follow-up**

The patients were followed at the outpatient clinic every 6 months during the first year after the procedure. Thereafter they were instructed to contact the laboratory in case of recurrent PSVT or rapid palpitations similar to the spontaneous episodes.

### **Statistics**

All continuous variables were presented as mean  $\pm$  standard deviation and all categorical variables were presented as number of patients and percentages. For all continuous variables the comparisons between the four study groups were done using one-way analysis of variance (ANOVA) and for categorical variables using Cramer's V under chi-square analysis. For all statistical analyses a *P* value  $< 0.05$  was considered statistically significant. The SPSS statistical package was used to perform all statistical analyses (SPSS Inc., Chicago, IL, USA).

## **Results**

### **Patient characteristics [Table 1]**

The patient population comprised 554 females (61.5 %) and 347 males (38.5%), ranging in age from 9 to 92 years (mean 50.8  $\pm$  18.2). Thirty-seven patients (4.1%) were  $\leq 18$  years old and 85 (9.4%) were  $\geq 75$ . Group 1 was the youngest and group 4 the oldest (*P* < 0.0005 for trend). Underlying heart disease was present in 75 patients (8.3%) including coronary artery disease (6.7%), valvular heart disease (1.0%), cardiomyopathy (0.2%), and miscellaneous diseases (0.4%).

### **Electrophysiologic characteristics**

During electrophysiologic study, 140 patients were found to have an associated arrhythmia which was also subjected to RFA: 91 patients (10.1%) had atrial tachyarrhythmias, 25 (2.8 %) had an accessory pathway, 20 (2.4%) had idiopathic right or left outflow tract ventricular arrhythmias, 3 (0.4%) had post-myocardial infarction ventricular tachycardia, and one patient had idiopathic left ventricular tachycardia ("Belhassen type").

The mechanism of tachycardia during electrophysiologic study was slow/fast ("typical") AVNRT in 833 patients (92.5%), fast/slow ("atypical") AVNRT in 23 (2.6%), slow/intermediate AVNRT in 17 (1.9%) and slow/fast and fast/slow AVNRT in 7 (0.8%), while it involved various slow pathways in 21 patients (2.3%). There were no significant differences between the study groups in terms of associated arrhythmia or AVNRT mechanism.

### **Catheter ablation results**

RFA was acutely successful in 877 patients (97.3%); slow pathway ablation was achieved in 452 patients (51.5%) and slow pathway

PSVT = paroxysmal supraventricular tachycardia

**Table 1.** Patient characteristics and results of the ablation procedure

Study patients' (n=901)	Group 1 (n=225)	Group 2 (n=225)	Group 3 (n=226)	Group 4 (n=225)	P
<b>Patients' characteristics</b>					
Female prevalence, 61.5%	64.4%	60.4%	62.4%	58.7%	0.622
Mean age (yrs), $50.8 \pm 18.2$	$43.7 \pm 15.3$	$50.2 \pm 16.9$	$53.1 \pm 18.9$	$56.5 \pm 18.9$	<0.0005
Patients aged $\leq 18$ years, 4.1%	5.8%	4.4%	4.0%	2.2%	0.296
Patients aged $\geq 75$ years, 9.4%	0.4%	5.3%	12.8%	19.1%	<0.0005
Organic heart disease, 8.3%	3.6%	7.1%	9.3%	13.3%	0.002
<b>Acute procedure results</b>					
Success, 877 (97.3%)	220 (97.8%)	218 (96.9%)	220 (97.3%)	219 (97.3%)	0.952
Failure, 10 (1.1%)	3 (1.3%)	3 (1.3%)	2 (0.9%)	2 (0.9%)	0.938
Discontinued, 14 (1.6%)	2 (0.9%)	4 (1.8%)	4 (1.8%)	4 (1.8%)	0.833
<b>No of successful RF pulses</b>					
$5.0 \pm 5.9$	$4.6 \pm 4.7$	$5.2 \pm 6.4$	$5.7 \pm 6.5$	$4.5 \pm 5.8$	0.087
<b>Successful P1-P2 locations</b>					
807 (92.1%)	190 (86.4%)	199 (91.7%)	207 (94.1%)	211 (96.3%)	0.001
<b>No. of catheters used</b>					
2 catheters, 584 (64.8%)	26 (11.6%)	184 (81.8%)	189 (83.6%)	185 (82.2%)	<0.0005
> 2 catheters, 317 (35.2%)	199 (88.4%)	41 (18.2%)	37 (16.4%)	40 (17.8%)	
<b>Procedure-related complications</b>					
None, 864 (95.9%)	216 (96.0%)	216 (96.0%)	220 (97.3%)	212 (94.2%)	0.1
$\geq II$ degree AV block, 31 (3.4%)	5 (2.2%)	9 (4.0%)	5 (2.2%)	12 (5.3%)	NS
Requiring permanent pacemaker, 8 (0.9%)	2 (0.9%)	3 (1.3%)	2 (0.9%)	1 (0.4%)	NS
Miscellaneous (n=6, 0.7%)	4 (1.8%)	0	1 (0.4%)	1 (0.4%)	NS

modification in 411 (46.9%) while in the remaining 14 patients (1.6%) various combinations of pathways were ablated. In 14 patients (1.6%) the procedure was discontinued before AVNRT elimination due to either of the following: a) the patient's desire or the physician's fear of inducing AV block; b) catheter-induced mechanical trauma to fast and/or slow AV nodal pathway. In 10 patients (1.1%) the procedure failed following multiple attempts. No significant difference between the study groups was found with regard to procedural success [Table 1].

The great majority (92.1%) of slow pathways were ablated at posterior sites (P1-P2) close to the coronary sinus ostium [4]. The mean number of RF applications given to achieve successful ablation was  $5.0 \pm 5.9$ . No significant difference between the study groups was found in terms of the number of successful ablation pulses.

A "two-catheter approach" was used in 584 patients (64.8%) while a multi-catheter approach was used in the remaining 317 (35.2%). A "two-catheter approach" was more frequently performed in the last three patient groups as compared to the first group ( $P < 0.0005$  for trend) [Table 1]. However, there were no significant differences in terms of procedure success rate or complications (mainly AV block) between the "two-catheter" and the multi-catheter groups.

#### Procedural complications

No complications were observed in 864 patients (95.9%). In 31 patients (3.4%) transient or permanent second- or third-degree AV block occurred during the procedure. Eight of these 31 patients (26%), representing 0.9% of all study patients, required pacemaker implantation (n=7) or upgrade of a previously implanted VVI

pacemaker (n=1) during the month following ablation. These 8 patients, six females and two males, ranged in age from 34 to 86 years (mean  $60.5 \pm 17.1$ ). During temporary pacemaker insertion the youngest of these patients (a 34 year old woman) also developed hemomediastinum that slowly resolved without additional intervention. There were no significant differences between the study groups in terms of occurrence rate of AV block [Table 1]. A significant pericardial effusion occurred in two patients (0.2%). In one of these patients, tamponade requiring pericardiocentesis developed and was attributed to the introduction of a diagnostic catheter in the right ventricle. In another patient with ischemic heart disease, myocardial ischemia was observed during the procedure.

Significant late complications occurred in 6 patients (0.7%): deep femoral vein thrombosis (n=2), pulmonary embolism (n=1), pneumothorax after pacemaker implantation (n=1), severe dermatitis (n=1) and a large groin hematoma (n=1). Excluding transient AV blocks, no significant complications were observed in patients under age 34 whereas significant complications occurred in 1.6% of patients aged  $\geq 34$  years old ( $P = 0.09$ ).

#### PSVT recurrences during follow-up

Recurrent PSVT was documented during follow-up in 25 patients (2.8%), including 22 who had an initial successful ablation procedure; in 2 the procedure failed and in one the procedure had to be discontinued. Of these 25 patients, 17 underwent a repeat successful RFA of the slow pathway (15 in our laboratory) with no arrhythmia recurrence, and 2 patients underwent intentional RFA of the AV node with pacemaker implantation; repeat RFA failed in 1 patient and was discontinued in another. Of the four remaining patients, three opted for medical therapy while one patient is scheduled for repeat RFA in our laboratory.

## Discussion

#### Main findings

The present study confirms the safety and efficacy of RFA of AVNRT. We found a high acute success rate (97.3%), a low recurrence rate (2.8%), and a relatively low incidence of complications (4.1%) and need for permanent cardiac pacing (0.9%). Finally, no significant complications were observed in the group of patients under 34 years old.

### Comparison with previous reports

During the last decade several studies reporting the results of RFA of AVNRT have been published. The success, the frequency of arrhythmia recurrence, and incidence of major complications reported in the present study are similar to results from these prior reports including multi-center studies [2-15]. To the best of our knowledge, our study is the largest single-center study ever reported. Interestingly, our results showed that the learning curve rates were rapidly achieved with a very high success rate obtained in the first study quartile (96%), which remained stable over the years.

### Two-catheters vs. multi-catheter technique

In most laboratories, RFA of AVNRT is performed after introduction of multiple diagnostic catheters in the high right atrium/coronary sinus, His bundle area, and right ventricular apex, along with an ablation catheter. This multi-catheter approach affords optimal documentation of dual AV node physiology, easy pacing from multiple sites and enables safe emergency pacing in case of occurrence of complete AV block. In addition, the continuous documentation during RF application of the His bundle activity as compared to the position of the ablation catheter is expected to increase the safety of the procedure. In the present study, a "two-catheter" approach (a diagnostic catheter in the right atrium and the ablation catheter) was performed in about two-thirds of our patients. No significant differences in terms of procedure success rate and complications were found using this two-catheter approach as compared to the multi-catheter approach. This two-catheter approach has the advantages of reducing procedure time and cost, patient discomfort and probably exposure to X-ray.

### Comparison between the different study groups

A significant progressive increase in the age of patients and associated cardiac disease was found over time in the various study groups. However, this did not result in an increased rate of procedure failure or complications over time, unlike results reported by others [12]. On the contrary, the results observed in our last group of patients were the best, as reflected by the lower incidence of iatrogenic AV block requiring pacemaker implantation (0.4%).

### RFA as first-line therapy

RFA improves health-related quality of life to a greater extent than do medications [18,19] and was the least expensive therapy as compared to drug therapy options among patients who have monthly episodes of PSVT. AVNRT is readily amenable to definitive therapy by catheter-based RF energy delivery at the slow pathway area. Results from the present and other series [2-15] have shown this strategy to be both safe and effective, supporting ablation therapy as first-line therapy for the majority of patients, especially young patients.

### Study limitations

The patients were followed every 6 months during the first year following the procedure, and were instructed to contact the labo-

ratory only in case of recurrent PSVT or rapid palpitations similar to the spontaneous episodes. Therefore, one cannot exclude a recurrent arrhythmia rate higher than what we observed. In addition, we did not take into account the occurrence of extrasystolic palpitations, which are commonly observed during follow-up, since these have been shown to be poor predictors of PSVT recurrence [20].

### Conclusions

The results of this single-center large-size study in patients with a wide age range confirm the extraordinary efficacy and relative safety of RFA of AVNRT, especially in young patients in whom it should be offered as first-line therapy. In addition, we found that the use of a "two-catheter" approach (one diagnostic and one ablation) was as effective and safe as a multi-catheter approach.

**Acknowledgments.** We thank Dr. R. Fish for his invaluable help and support in designing our computerized electrophysiologic program. We also thank Dr. M. Ilan (Shaare Zedek Medical Center, Jerusalem), Dr. R. Fish and Dr. R. Rosso for their help in the management of some of the patients in the study.

### References

1. Kwaku KF, Josephson ME. Typical AVNRT – an update on mechanisms and therapy. *Cardiac Electophys Rev* 2002;6:414-21.
2. Lee MA, Morady F, Kadish A, et al. Catheter modification of the atrioventricular junction with radiofrequency energy for control of atrioventricular nodal reentry tachycardia. *Circulation* 1991;83:827-35.
3. Haissaguerre M, Gaita F, Fischer B, et al. Elimination of atrioventricular nodal reentrant tachycardia using discrete slow potentials to guide application of radiofrequency energy. *Circulation* 1992;85:2162-75.
4. Jackman WM, Beckman KJ, McClelland JH, et al. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry, by radiofrequency catheter ablation of slow-pathway conduction. *N Engl J Med* 1992;327:313-18.
5. Jazayeri MR, Hempe SL, Sra JS, et al. Selective transcatheter ablation of the fast and slow pathways using radiofrequency energy in patients with atrioventricular nodal reentrant tachycardia. *Circulation* 1992;85:1318-28.
6. Kay GN, Epstein AE, Dailey SM, Plumb VJ. Selective radiofrequency ablation of the slow pathway for the treatment of atrioventricular nodal reentrant tachycardia. Evidence for involvement of perinodal myocardium within the reentrant circuit. *Circulation* 1992;85:1675-88.
7. Kalbfleisch SJ, Strickberger SA, Williamson B, et al. Randomized comparison of anatomic and electrogram mapping approaches to ablation of the slow pathway of atrioventricular node reentrant tachycardia. *J Am Coll Cardiol* 1994;23:716-23.
8. Epstein LM, Lesh MD, Griffin JC, Lee RJ, Scheinman MM. A direct midseptal approach to slow atrioventricular nodal pathway ablation. *Pacing Clin Electrophysiol* 1995;18:57-64.
9. Kottkamp H, Hindricks G, Willems S, et al. An anatomically and electrogram-guided stepwise approach for effective and safe catheter ablation of the fast pathway for elimination of atrioventricular node reentrant tachycardia. *J Am Coll Cardiol* 1995;25:974-81.
10. Hindricks G. Incidence of complete atrioventricular block following attempted radiofrequency catheter modification of the atrioventricular node in 880 patients. Results of the Multicenter European Radiofrequency Survey (MERFS) The Working Group on

- Arrhythmias of the European Society of Cardiology. *Eur Heart J* 1996;17:82–8.
11. Yu WC, Chen SA, Tai CT, et al. Radiofrequency catheter ablation of slow pathway in 760 patients with atrioventricular nodal reentrant tachycardia – long term results. *Zhonghua Yi Xue Za Zhi* 1997;59:71–7.
  12. Boulos M, Hoch D, Schechter S, Greenberg S, Levine J. Age dependence of complete heart block complicating radiofrequency ablation of the atrioventricular nodal slow pathway. *Am J Cardiol* 1998;82:390–1.
  13. Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. *Circulation* 1999;99:262–70.
  14. Erdogan A, Schulte B, Carlsson J, et al. Clinical characteristics of patients with AV-nodal reentrant tachycardia (AVNRT): modification by high frequency catheter ablation. Study of 748 patients after high frequency catheter ablation. *Med Klin* 2001;96:708–12.
  15. Sciarra L, Mantovan R, Verlato R, et al. Radiofrequency ablation of atrioventricular nodal reentrant tachycardia: the risk of intra-procedural, late and long term atrioventricular block. The Veneto region multicenter experience. *Ital Heart J* 2002;3:715–20.
  16. Belhassen B, Fish R, Glikson M, et al. Noninvasive diagnosis of dual AV node physiology in patients with AV nodal reentrant tachycardia by administration of adenosine-5'-triphosphate during sinus rhythm. *Circulation* 1998;98:47–53.
  17. Wu D, Yeh SJ, Wang CC, Wen MS, Lin FC. A simple technique for selective radiofrequency ablation of the slow pathway in atrioventricular node reentrant tachycardia. *J Am Coll Cardiol* 1993;21:1612–21.
  18. Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. *Ann Intern Med* 2000;133:864–76.
  19. Bathina MN, Mickelsen S, Brooks C, Jaramillo J, Hepton T, Kusumoto FM. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. *Am J Cardiol* 1998;82:589–93.
  20. Mann DE, Kelly PA, Adler SW, Fuenzalida CE, Reiter MJ. Palpitations occur frequently following radiofrequency catheter ablation for supraventricular tachycardia, but do not predict pathway recurrence. *Pacing Clin Electrophysiol* 1993;16:1645–9.
- 
- Correspondence:** Dr. B. Belhassen, Dept. of Cardiology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel.  
Phone/Fax: (972-3) 697-4418  
email: bblhass@tasmc.health.gov.il